Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AYTU BioScience Announces Receipt of Initial Shipment of 100,000 COVID-19 IgG/IgM Point-of-Care Rapid Tests; Additional 500,000 Tests on Order
Initial Shipment of 2-10 Minute COVID-19 Rapid Tests Received at Company's Englewood, Colorado Facility
ENGLEWOOD, CO / ACCESSWIRE / April 1, 2020 / Aytu BioScience, Inc. (AYTU),(the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has received its first Coronavirus Disease 2019 ("COVID-2019") IgG/IgM Rapid Test shipment containing 100,000 tests from the manufacturer. The Company is now in the process of relabeling the test kits to comply with Food and Drug Administration (FDA) requirements relating to labeling of COVID-19 serology test kits and expects to begin filling current backorders and additional incoming orders shortly thereafter.
Additionally, the Company expects to receive another 500,000 rapid tests from the manufacturer in the next two to three weeks in order to fulfill additional customer orders.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "We're pleased to have the first 100,000 tests now in stock at our facility in Englewood, Colorado. The Company is now preparing the kits for shipment to customers. Following the completion of the labeling process and final clearance by FDA, we'll be shipping this initial inventory to healthcare professionals across the country. While preparing these kits for distribution, we are also preparing to receive our next shipment of 500,000 tests."
The COVID-19 IgG/IgM Rapid Test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 126 patient clinical trial and is CE marked. The COVID-19 IgG/IgM Rapid Test is registered with the FDA and listed on the FDA website as one of the serology tests allowed by the agency to be commercialized in the United States. The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu recently acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 113 patient clinical trial and has received CE marking.
Aytu recently acquired Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the Company's proprietary Beyond Human® marketing and sales platform.
Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit http://aytubio.com and visit http://innovuspharma.com to learn about the Company's consumer healthcare products.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: market and other conditions, the regulatory and commercial risks associated with introducing the COVID-19 IgG/IgM Rapid Test, shipping delays and their impact on our ability to introduce the COVID-19 IgG/IgM Rapid Test, our ability to enforce our exclusive rights to distribute the COVID-19 IgG/IgM Rapid Test in the jurisdictions set forth in the distribution agreement, the ability of the COVID-19 IgG/IgM Rapid Test to accurately and reliably test for COVID-19, the manufacture of the COVID-19 IgG/IgM Rapid Test's ability to manufacture such testing kits on a high volume scale, manufacturing problems or delays related to the COVID-19 IgG/IgM Rapid Test, our ability to satisfy any labelling conditions or other FDA or other regulatory conditions to sell the COVID-19 IgG/IgM Rapid Test Kit, the ability to obtain a sufficient number of COVID-19 IgG/IgM Rapid Test kits to meet demand if any, the demand or lack thereof for the COVID-19 IgG/IgM Rapid Test Kit, effects of the business combination of Aytu and the Commercial Portfolio and the recently completed merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Commercial Portfolio, the ultimate timing, outcome and results of integrating the operations the Commercial Portfolio and Innovus with Aytu's existing operations, risks relating to gaining market acceptance of our products, obtaining or maintaining reimbursement by third-party payors for our prescription products, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.
Contact for Media and Investors:
James Carbonara
Hayden IR
(646) 755-7412
mailto://james@haydenir.com
Contact for COVID-19 IgG/IgM Rapid Test-Related Inquiries:
mailto://COVID-19@aytubio.com
SOURCE: Aytu BioScience, Inc.
View source version on accesswire.com:
https://www.accesswire.com/583399/Aytu-BioScience-Announces-Receipt-of-Initial-Shipment-of-100000-COVID-19-IgGIgM-Point-of-Care-Rapid-Tests-Additional-500000-Tests-on-Order
$AYTU BioScience Announces Receipt of Initial Shipment of 100,000 COVID-19 IgG/IgM Point-of-Care Rapid Tests; Additional 500,000 Tests on Order
Initial Shipment of 2-10 Minute COVID-19 Rapid Tests Received at Company's Englewood, Colorado Facility
ENGLEWOOD, CO / ACCESSWIRE / April 1, 2020 / Aytu BioScience, Inc. (AYTU),(the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has received its first Coronavirus Disease 2019 ("COVID-2019") IgG/IgM Rapid Test shipment containing 100,000 tests from the manufacturer. The Company is now in the process of relabeling the test kits to comply with Food and Drug Administration (FDA) requirements relating to labeling of COVID-19 serology test kits and expects to begin filling current backorders and additional incoming orders shortly thereafter.
Additionally, the Company expects to receive another 500,000 rapid tests from the manufacturer in the next two to three weeks in order to fulfill additional customer orders.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "We're pleased to have the first 100,000 tests now in stock at our facility in Englewood, Colorado. The Company is now preparing the kits for shipment to customers. Following the completion of the labeling process and final clearance by FDA, we'll be shipping this initial inventory to healthcare professionals across the country. While preparing these kits for distribution, we are also preparing to receive our next shipment of 500,000 tests."
The COVID-19 IgG/IgM Rapid Test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 126 patient clinical trial and is CE marked. The COVID-19 IgG/IgM Rapid Test is registered with the FDA and listed on the FDA website as one of the serology tests allowed by the agency to be commercialized in the United States. The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu recently acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 113 patient clinical trial and has received CE marking.
Aytu recently acquired Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the Company's proprietary Beyond Human® marketing and sales platform.
Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit http://aytubio.com and visit http://innovuspharma.com to learn about the Company's consumer healthcare products.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: market and other conditions, the regulatory and commercial risks associated with introducing the COVID-19 IgG/IgM Rapid Test, shipping delays and their impact on our ability to introduce the COVID-19 IgG/IgM Rapid Test, our ability to enforce our exclusive rights to distribute the COVID-19 IgG/IgM Rapid Test in the jurisdictions set forth in the distribution agreement, the ability of the COVID-19 IgG/IgM Rapid Test to accurately and reliably test for COVID-19, the manufacture of the COVID-19 IgG/IgM Rapid Test's ability to manufacture such testing kits on a high volume scale, manufacturing problems or delays related to the COVID-19 IgG/IgM Rapid Test, our ability to satisfy any labelling conditions or other FDA or other regulatory conditions to sell the COVID-19 IgG/IgM Rapid Test Kit, the ability to obtain a sufficient number of COVID-19 IgG/IgM Rapid Test kits to meet demand if any, the demand or lack thereof for the COVID-19 IgG/IgM Rapid Test Kit, effects of the business combination of Aytu and the Commercial Portfolio and the recently completed merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Commercial Portfolio, the ultimate timing, outcome and results of integrating the operations the Commercial Portfolio and Innovus with Aytu's existing operations, risks relating to gaining market acceptance of our products, obtaining or maintaining reimbursement by third-party payors for our prescription products, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.
Contact for Media and Investors:
James Carbonara
Hayden IR
(646) 755-7412
mailto://james@haydenir.com
Contact for COVID-19 IgG/IgM Rapid Test-Related Inquiries:
mailto://COVID-19@aytubio.com
SOURCE: Aytu BioScience, Inc.
View source version on accesswire.com:
https://www.accesswire.com/583399/Aytu-BioScience-Announces-Receipt-of-Initial-Shipment-of-100000-COVID-19-IgGIgM-Point-of-Care-Rapid-Tests-Additional-500000-Tests-on-Order
Make that $1.65 now DD! Nice
Awesome find!
wire
Exactly right! AYTU has a CE mark, which I really haven't seen anyone discussing. And I need to go back and see if Dragon Lady had already mentioned this.
"This point-of-care test has been validated in a 126 patient clinical trial and is CE marked".
This could be huge if they are able to take advantage of it! But we do have to take care of ourselves first.
CE marking is a certification mark that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA).
https://www.innovationews.com/Aytu-BioScience-gets-FDA-approval-to-begin-distribution-of-COVID-19-rapid-tests/
Thursday March 26, 2020 0 comments Tags: Englewood, Aytu BioScience, John Disbrow, COVID-19
ENGLEWOOD -- Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced it has received confirmation from the U.S. FDA that the company may begin distribution of its Coronavirus Disease 2019 ("COVID-2019") IgG/IgM Rapid Test throughout the United States.
The COVID-19 Rapid Test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care.
Aytu said it expects delivery of its first shipment of 100,000 tests this week. The company has been in discussions with healthcare distributors, healthcare institutions, medical practices, and government agencies and is working quickly to begin distribution into the U.S. healthcare supply chain.
"We are moving as quickly as we can to bring the COVID-19 IgG/IgM Rapid Test to the U.S. professional medical community,” said John Disbrow, Aytu’s CEO.
“With product now in transit to our warehouse in Colorado, we're optimistic that we can have test kits ready for sale in the very near term.
“In the two short weeks since signing our distribution agreement, we have ordered our first 100,000 tests and have received confirmation from FDA that we may begin distribution.
“We are optimistic that we're now just days away from placing these COVID-19 test kits into the hands of healthcare professionals."
The COVID-19 IgG/IgM Rapid Test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma.
This point-of-care test has been validated in a 126 patient clinical trial and is CE marked.
AYTU TEST ON CBS THIS MORNING
SKIP TO 4:55 AND WATCH ALL THE WAY TO THE END
Awesome news!
wire
GCGX tweet $1.4M in Revs
https://twitter.com/Global_GCGXOTC
GCGX tweet $1.4M in Revs
https://twitter.com/Global_GCGXOTC
GCGX tweet $1.4M in Revs
https://twitter.com/Global_GCGXOTC
Outstanding tweet!
wire
Excellent post! A must read by all.
wire
$AYTU--New Price Target of $4.88
https://dbtnews.com/2020/03/24/why-aytu-bioscience-inc-aytu-is-a-good-choice-for-investors-after-new-price-target-of-4-88/
why Aytu BioScience Inc. [AYTU] is a Good Choice for Investors After New Price Target of $4.88
Aytu BioScience Inc. [NASDAQ: AYTU] jumped around 0.51 points on Monday, while shares priced at $1.87 at the close of the session, up 37.50%. Aytu BioScience Inc. stock is now 92.29% up from its year-to-date (YTD) trading value. AYTU Stock saw the intraday high of $1.99 and lowest of $1.65 per share. The company’s 52-week high price is 2.99, which means current price is +457.88% above from all time high which was touched on 03/10/20.
Compared to the average trading volume of 11.26M shares, AYTU reached a trading volume of 113446781 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Aytu BioScience Inc. [AYTU]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AYTU shares is $4.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AYTU stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Aytu BioScience Inc. is set at 0.43, with the Price to Sales ratio for AYTU stock in the period of the last 12 months amounting to 14.14. The Price to Book ratio for the last quarter was 1.93, with the Price to Cash per share for the same quarter was set at 0.08.
How has AYTU stock performed recently?
Aytu BioScience Inc. [AYTU] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.35. With this latest performance, AYTU shares gained by 148.34% in over the last four-week period, additionally plugging by 38.52% over the last 6 months – not to mention a rise of 4.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AYTU stock in for the last two-week period is set at 62.10, with the RSI for the last a single of trading hit 63.70, and the three-weeks RSI is set at 61.05 for Aytu BioScience Inc. [AYTU]. The present Moving Average for the last 50 days of trading for this stock 0.8785, while it was recorded at 1.5100 for the last single week of trading, and 1.1809 for the last 200 days.
Aytu BioScience Inc. [AYTU]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Aytu BioScience Inc. [AYTU] shares currently have an operating margin of -222.35 and a Gross Margin at +40.74. Aytu BioScience Inc.’s Net Margin is presently recorded at -370.64.
Return on Total Capital for AYTU is now -158.70, given the latest momentum, and Return on Invested Capital for the company is -264.54. Return on Equity for this stock declined to -264.54, with Return on Assets sitting at -97.28.
Reflecting on the efficiency of the workforce at the company, Aytu BioScience Inc. [AYTU] managed to generate an average of -$511,923 per employee. Receivables Turnover for the company is 6.31 with a Total Asset Turnover recorded at a value of 0.26.Aytu BioScience Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.10.
Earnings analysis for Aytu BioScience Inc. [AYTU]
With the latest financial reports released by the company, Aytu BioScience Inc. posted -0.5/share EPS, while the average EPS was predicted by analysts to be reported at -0.58/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 13.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AYTU.
Insider trade positions for Aytu BioScience Inc. [AYTU]
There are presently around $12 million, or 14.50% of AYTU stock, in the hands of institutional investors. The top three institutional holders of AYTU stocks are: ARMISTICE CAPITAL, LLC with ownership of 7,950,000, which is approximately 55.271% of the company’s market cap and around 1.00% of the total institutional ownership; SEARLE & CO., holding 272,437 shares of the stock with an approximate value of $371000.0 in AYTU stocks shares; and VANGUARD GROUP INC, currently with $130000.0 in AYTU stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Aytu BioScience Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 9 institutional holders increased their position in Aytu BioScience Inc. [NASDAQ:AYTU] by around 2,900,218 shares. Additionally, 7 investors decreased positions by around 196,094 shares, while 11 investors held positions by with 5,363,209 shares. The mentioned changes placed institutional holdings at 8,459,521 shares, according to the latest SEC report filing. AYTU stock had 4 new institutional investments in for a total of 4 shares, while 6 institutional investors sold positions of 196,093 shares during the same period.
I wish it was open tomorrow. lol
$INO volume really kicking into high gear.
$INO volume really kicking into high gear.
$INO volume really kicking into high gear.
$INO--Kate Broderick of INO is being interviewed on this Sunday's 60 Minutes
https://www.cbsnews.com/video/finding-a-covid-19-vaccine-and-drug-60-minutes-2020-03-15/?ftag=CNM-00-10aab7d&linkId=84663126
$INO--Kate Broderick of INO is being interviewed on this Sunday's 60 Minutes
https://www.cbsnews.com/video/finding-a-covid-19-vaccine-and-drug-60-minutes-2020-03-15/?ftag=CNM-00-10aab7d&linkId=84663126
$INO--Kate Broderick of INO is being interviewed on this Sunday's 60 Minutes
https://www.cbsnews.com/video/finding-a-covid-19-vaccine-and-drug-60-minutes-2020-03-15/?ftag=CNM-00-10aab7d&linkId=84663126
Only Gilead and Regeneron were mentioned during press conference.
Awesome find and article Wish!
wire
No doubt Opti, really sucks they do this.
wire
8pm EST
3rd Halt...WTH!
Resume trading!!
and is in discussions with a market maker who has expressed preliminary interest to work with the Company on its Form 211 filing to reinstate trading of the Company’s shares on the OTC Pinks.
wire
NEWS OUT!! Lans Holdings Plans to File Form 10 with the SEC and Target Reinstatement of its Symbol on OTC Pinks https://www.globenewswire.com/news-release/2019/09/20/1918533/0/en/Lans-Holdings-Plans-to-File-Form-10-with-the-SEC-and-Target-Reinstatement-of-its-Symbol-on-OTC-Pinks.html
September 20, 2019 09:00 ET | Source: Lans Holdings Inc.
MIAMI, FL, Sept. 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Lans Holdings Inc. is pleased to announce the completion of its temporary 10-day trading suspension. The Company now aims for the OTC Pinks as it continues to work on the acquisition of Global Stem Cells Group.
The Company continues to work with its auditors, accounting staff and outside consultants to bring the company’s filings current as soon as possible. Having lost its trading symbol, the Company intends to proceed directly to a relisting on the OTC Pink sheets. To that end, the company intends to complete its filings in conjunction with a Form 10 to re-register its common shares and is in discussions with a market maker who has expressed preliminary interest to work with the Company on its Form 211 filing to reinstate trading of the Company’s shares on the OTC Pinks.
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Lans Holdings Inc.
Lans Holdings offers payment solutions. The Company makes it easy for sellers to start selling, and buyers to buy with confidence. The Company plans to process credit card payments online. In time, the Company hopes to be known in the industry as a secure and reliable source of payment processing. With the Company's breadth of business structure experience and technology consultants, the Company aims to help projects and companies grow.
Further information on the Company can be found at www.sec.gov and the company's website at www.lans.holdings
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “plan”, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
investors@lans.holdings
Telephone: +1.786.789.5758
And LAHO is #3 on the Top 100 Issues
https://otce.finra.org/otce/marketStatistics/top100Issues
Issues huh?
wire
Dragon, I read your post about this on Friday and thought there might be hope in what you highlighted, except in the last one you posted on this 8k was the highlighted paragraph stating:
During the fiscal years ended November 30, 2016 and 2015, and through the interim period ended July 24, 2019, there were the following “reportable events” (as such term is defined in Item 304 of Regulation S-K). As disclosed in Part I, Item 4 of the Company’s Form 10-Q for the quarter ended September 30, 2018, the Company’s management determined that the Company’s internal controls over financial reporting were not effective as of the end of such period due to the existence of material weaknesses related to the following:
(i) inadequate segregation of duties and effective risk assessment; and
(ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.
These material weaknesses have not been remediated as of the date of this Current Report on Form 8-K.
However, they should have continued to follow-up or submit the appropriate extension/form alerting the SEC that they are currently working to get it squared away. They did nothing!
wire
Excellent news for this market ApollyonZ! And that article was just yesterday. Love it!
wire
All I know is that my brother and I combined grabbed about 60 milly in the 5s, 6s, and 7 range at the ask today.
wire
My bro just purchased 40M shares at 6’s and 7’s.
Grabbed a ton of 5’s myself...lovin it!
Excellent info A->Z! That is some great DD right there.
wire
You are correct sir and DNS verified as well.
wire
Very nice PennyPro!!